Zynex EBIT per Share
Delisted·Dec 23, 2025
The EBIT per Share of Zynex (ZYXI) as of Aug 25, 2026 is 0.19 USD. In the previous year, EBIT per Share was 0.34 USD — a change of -45.64% (lower).
Get this data via API
Financial Data API
EBIT per Share
0.19USD
YoY
-45.64%
Last updated:
EBIT per Share of Zynex is 2026 0.19 USD. EBIT per Share of Zynex was 2025 0.34 USD. It decreases by -45.64% lower compared to the previous year.
The Zynex EBIT per Share history
3 Years
10 Years
25 Years
Max
EBIT per Share
Date
EBIT per Share
Jan 1, 2022
0.60 USD
Jan 1, 2023
0.34 USD
Jan 1, 2024
0.19 USD
Jan 1, 2025 (e)
0.31 USD
Jan 1, 2026 (e)
0.34 USD
Jan 1, 2027 (e)
0.38 USD
Jan 1, 2028 (e)
0.41 USD
Jan 1, 2029 (e)
0.45 USD
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | 0.45USD | +9.45% |
| est | 0.41USD | +9.54% |
| est | 0.38USD | +9.78% |
| est | 0.34USD | +10.24% |
| est | 0.31USD | +67.71% |
| 0.19USD | -45.64% | |
| 0.34USD | -43.55% | |
| 0.60USD | +6.35% | |
| 0.57USD | +117.29% | |
| 0.26USD | -11.36% | |
| 0.30USD | +5.33% | |
| 0.28USD | +18.54% | |
| 0.24USD | +1,636.70% | |
| 0.01USD | -118.86% | |
| -0.07USD | -56.45% | |
| -0.17USD | -25.30% | |
| -0.22USD | -378.72% | |
| 0.08USD | -12.59% | |
| 0.09USD | +96.12% | |
| 0.05USD | -58.75% | |
| 0.11USD | +987.97% | |
| 0.01USD | -89.45% | |
| 0.10USD | -1,861.30% | |
| -0.01USD | -2,115.36% | |
| 0.00USD | — |
Access this data via the Eulerpool API
Zynex Stock analysis
What does Zynex do? Zynex Inc is an American company that manufactures and distributes medical devices and accessories. The company was founded in 1996 and is headquartered in Englewood, Colorado. In recent years, it has become a major player in the pain therapy market.
The history of Zynex began with the development of a neurotherapeutic system called NeuroMove, which aimed to restore mobility in patients with paralysis after strokes or other neurological disorders. The company uses proprietary technology to provide safe and effective electrotherapeutic stimulation, which helps trigger muscle contractions and improve mobility.
Over the years, the company has specialized in the development and sale of medical devices for pain therapy and rehabilitation. Zynex's products can be used in various areas, including electrostimulation, TENS and EMS therapy, home diagnostics, as well as blood pressure and oxygen measurement.
Zynex offers devices specifically for pain therapy. These devices are used by many doctors and physiotherapists to support patients in their healing process. The company's flagship product is the Nexus D-11 EMS and TENS device, which is capable of conducting multiple pain treatments simultaneously.
Another important device from Zynex is the InWave system, which applies FDA-approved electromagnetic wave therapy. The therapy is used for both acute and chronic pain and aims to promote the body's natural healing processes to relieve pain.
Zynex also manufactures home diagnostic devices such as the blood sugar monitor and pulse oximeter, which can be regularly used by patients at home to monitor their well-being. These products help individuals develop an understanding of how their body responds to different treatments or environmental conditions.
An important aspect of Zynex's business model is collaborating with healthcare customers. The company forms partnerships with medical facilities and practitioners to ensure that its products are effectively and safely utilized. These partnerships often include training programs to ensure that users of each device develop a basic understanding of how it works to ensure quality treatment.
Zynex has also established a subsidiary called Zynex Medical Europe, which operates in European regions. The company is based in the Netherlands and is responsible for marketing and distributing Zynex's products in Europe.
Overall, Zynex has established itself as a key player in the field of pain therapy and rehabilitation. Through its innovative technology and healthcare partnerships, the company is able to provide the best possible patient care. Zynex is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Zynex stock
EBIT per Share of Zynex is 0.19 USD in 2026.
EBIT per Share of Zynex changed from 0.34 USD to 0.19 USD, representing a -45.64% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Zynex since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Zynex
All Key Metrics — Zynex
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth